RZLT - NASDAQ

Rezolute, Inc.

RZLT·NASDAQ

$4.38

+9.6%

HealthcareBiotechnology

Rezolute, Inc., a clinical stage biopharmaceutical company, develops transformative therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, a selective and potent plasma kallikrein inhibitor, which is in Phase 1 clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$422.24M

EPS-0.9800

P/E Ratio-4.47

Earnings Date09/10/2026

rzlt

Total Liabilities

Last Annual Value

13.36M

3-Year CAGR

65%

5-Year CAGR

30%

10-Year CAGR

20%

Adjust for Inflation

Rezolute, Inc. Competitors Analysis of Total Liabilities

RZLT · NASDAQ

Company	Total Liabilities	CAGR 3Y	CAGR 5Y	CAGR 10Y
Rezolute, Inc. NASDAQ:RZLT	13.36M	21.0%	-4.1%	20.2%
Tyra Biosciences, Inc. NASDAQ:TYRA	23.43M	2.8%	36.4%	N/A
Geron Corporation NASDAQ:GERN	344.67M	33.1%	28.2%	45.9%
Kura Oncology, Inc. NASDAQ:KURA	564.23M	121.9%	83.1%	45.9%
Prime Medicine, Inc. NASDAQ:PRME	221.87M	54.0%	28.9%	N/A
EyePoint Pharmaceuticals, Inc. NASDAQ:EYPT	57.88M	-13.3%	-6.0%	18.3%
Savara Inc. NASDAQ:SVRA	50.30M	10.6%	9.4%	-2.5%
Day One Biopharmaceuticals, Inc. NASDAQ:DAWN	66.67M	31.2%	50.4%	N/A
ProKidney Corp. NASDAQ:PROK	34.78M	6.0%	21.1%	N/A
Maravai LifeSciences Holdings, Inc. NASDAQ:MRVI	397.87M	-17.1%	-21.9%	N/A

Rezolute, Inc. Fair Value Envelope

RZLT · NASDAQ

Our analysis suggests that RZLT has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.385, this represents a potential HIDDEN relative to our calculated worth for Rezolute, Inc..

HIDDEN

Intrinsic Value

Current Price: $4.385

Related Guides

Blog Categories

Continue your RZLT research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.